Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 28

Sort by

Sort Order Select

Journal Articles

Cite-Seq Profiling of T Cells in Multiple Myeloma Patients Undergoing BCMA Targeting CAR-T or Bites Immunotherapy

Noemie Leblay, PhD, Ranjan Maity, PhD, Elie Barakat, Sylvia McCulloch, MD MSc, Peter Duggan, MD FRCPC, Victor Jimenez-Zepeda, MD, Nizar J. Bahlis, MD, Paola Neri, MD

Blood (2020) 136 (Supplement 1): 11–12.

https://doi.org/10.1182/blood-2020-137650

Published: 2020

Journal Articles

Is Tandem ASCT Needed in MM Patients with High Risk Cytogenetics in the Era of Maintenance Therapy? Results from the Canadian Myeloma Research Group (CMRG) Database

Peter Duggan, MD FRCPC, Donna E. Reece, MD, Kevin Song, MD, Victor Jimenez-Zepeda, MD, Arleigh McCurdy, MD BSc, Martha L Louzada, MDMSc, Hira S Mian, MD, Michael Sebag, MD PhD FRCPC, Darrell J White, MD, Julie Stakiw, MD, Richard Leblanc, MD FRCPC, Esther Masih-Khan, Eshetu G Atenafu, M.Sc., P.Stat, Rami Kotb, MD, Muhammad Aslam, MD, Anthony Reiman, MD, Engin Gul, BS, MBA, Christopher P. Venner, MD

Blood (2020) 136 (Supplement 1): 18–19.

https://doi.org/10.1182/blood-2020-139689

Published: 2020

Journal Articles

Bortezomib-Maintenance for Patients with AL Amyloidosis: A Single Center Experience

Victor Jimenez-Zepeda, MD, Peter Duggan, MD FRCPC, Paola Neri, MD, Jason Tay, MD FRCPC, Nizar J. Bahlis, MD

Blood (2017) 130 (Supplement 1): 3151.

https://doi.org/10.1182/blood.V130.Suppl_1.3151.3151

Published: 2017

Journal Articles

Early Relapse in Transplant-Eligible MM Patients Undergoing Auto-SCT Followed By Maintenance Therapy

Victor Jimenez-Zepeda, MD, Peter Duggan, MD FRCPC, Paola Neri, MD, Jason Tay, MD FRCPC, Nizar J. Bahlis, MD

Blood (2017) 130 (Supplement 1): 5523.

https://doi.org/10.1182/blood.V130.Suppl_1.5523.5523

Published: 2017

Journal Articles

Post-Autologous Stem Cell Transplantation Therapy for Multiple Myeloma Patients: Impact on Clinical Outcomes

Victor Jimenez-Zepeda, MD, Peter Duggan, MD FRCPC, Paola Neri, MD, Jason Tay, MD FRCPC, Sylvia McCulloch, MD, Nizar J. Bahlis, MD

Blood (2017) 130 (Supplement 1): 5524.

https://doi.org/10.1182/blood.V130.Suppl_1.5524.5524

Published: 2017

Journal Articles

Single Cell Resolution Profiling Defines the Innate and Adaptive Immune Repertoires Modulated By Daratumumab and IMiDs Treatment in Multiple Myeloma (MM)

Paola Neri, MD, Ranjan Maity, PhD, Ines Tagoug, PhD, Peter Duggan, MD FRCPC, Sylvia McCulloch, MD, Victor Jimenez-Zepeda, MD, Jason Tay, MD FRCPC, Lawrence H. Boise, PhD, Anjan Thakurta, PhD, Nizar J. Bahlis, MD

Blood (2017) 130 (Supplement 1): 123.

https://doi.org/10.1182/blood.V130.Suppl_1.123.123

Published: 2017

Journal Articles

Phase I/II Study of Infusional Gemcitabine and High-Dose Melphalan Conditioning Prior to Autologous Stem Cell Transplantation for Patients with Relapsed/Refractory Lymphoma: Interim Safety Analysis

Marta Davidson, MDPhD, Douglas A. Stewart, Peter Duggan, MD FRCPC, Andrew Daly, MD, Mona Shafey, MD

Blood (2017) 130 (Supplement 1): 4534.

https://doi.org/10.1182/blood.V130.Suppl_1.4534.4534

Published: 2017

Journal Articles

Minimal Residual Disease (MRD) Assessed By Flow Cytometry in Patients with AL Amyloidosis Treated with Cyclophosphamide, Bortezomib and Dexamethasone (CyBorD)

Victor Jimenez-Zepeda, MD, Peter Duggan, MD FRCPC, Paola Neri, MD, Jason Tay, MD FRCPC, Nizar J. Bahlis, MD

Blood (2017) 130 (Supplement 1): 1836.

https://doi.org/10.1182/blood.V130.Suppl_1.1836.1836

Published: 2017

Journal Articles

The Evolving Impact on Survival Outcomes in Multiple Myeloma with Greater Access to Novel Treatment Regimens: Experience in a Real-World Cohort

Zack M. Breckenridge, BSc, Victor Jimenez-Zepeda, MD, Nizar J. Bahlis, MD, Paola Neri, MD, Irwindeep Sandhu, MDFRCPC, Michael P. Chu, MD, Ismail Ismail, Jason Tay, MD FRCPC, Peter Duggan, MD FRCPC, Andrew Belch, Joanne D. Hewitt, NP, PhD, Linda M. Pilarski, PhD, Tatiana Nikitina, Christopher P. Venner

Blood (2017) 130 (Supplement 1): 1859.

https://doi.org/10.1182/blood.V130.Suppl_1.1859.1859

Published: 2017

Journal Articles

Impact of ABO Incompatibility on Engraftment in Allogeneic Hematopoietic Stem Cell Transplantation

Oksana Prokopchuk-Gauk, MD FRCPC, Joanna McCarthy, MLT, Peter Duggan, MD FRCPC, Meer-Taher Shabani-Rad, MD FRCPC, Nicole L Prokopishyn, PhD

Blood (2016) 128 (22): 3394.

https://doi.org/10.1182/blood.V128.22.3394.3394

Published: 2016

Journal Articles

Development of Second Primary Malignancies in Multiple Myeloma Patients Treated with Lenalidomide: An Alberta Perspective

Katherine Fung, BSP, ACPR, Peter Duggan, MD FRCPC, Carole Chambers, BScPharm, MBA, FCSHP, FISOPP, Patrick Shui-Lun Yau, BPharm, Deonne Dersch-Mills, BScPharm, ACPR, PharmD, Frances Cusano, BScPharm, ACPR, Nizar J Bahlis, Sunita Ghosh, PhD, P.Stat.

Blood (2016) 128 (22): 4528.

https://doi.org/10.1182/blood.V128.22.4528.4528

Published: 2016

Journal Articles

BK Virus Hemorrhagic Cystitis Is Associated with Graft Versus Host Disease and Increased Health Care Resource Utilization in Patients Undergoing Allogeneic Stem Cell Transplantation

Wilson Lam, MD, Jan Storek, MD PhD, Nizar J Bahlis, MD, Christopher Brown, MD, Peter Duggan, MD FRCPC, Michelle Geddes, MD FRCPC, Mary Lynn Savoie, MD FRCPC, Mona Shafey, MD FRCPC, Douglas A. Stewart, MD FRCPC, Andrew Daly, MD FRCPC

Blood (2014) 124 (21): 3901.

https://doi.org/10.1182/blood.V124.21.3901.3901

Published: 2014

Journal Articles

Outcomes and Correlative Studies Of a Phase I Trial With The Oral PARP1-2 Inhibitor Veliparib In Combination With Bortezomib In Patients With Relapsed Or Refractory Multiple Myeloma

Paola Neri, MD, PhD, Peter Duggan, MD, FRCPC, Kathy Gratton, Li Ren, PhD, Douglas A. Stewart, MD, FRCP, Jonathan J Keats, PhD, Nizar J. Bahlis, MD

Blood (2013) 122 (21): 1978.

https://doi.org/10.1182/blood.V122.21.1978.1978

Published: 2013

Journal Articles

Fludarabine Metabolite Level On Day Zero Does Not Affect Outcomes Of Hematopoietic Cell Transplantation In Patients With Normal Renal Function

Cameron D. Griffiths, MD, Ella S.M Ng, MSc., Bill Kangarloo, MSc., Tyler S Williamson, PhD, Reanne Booker, BSc, MSN, NP, Ping Yue, MD, Peter Duggan, MD, FRCPC, Mary Lynn Savoie, MD, FRCPC, Christopher Brown, MD, Andrew Daly, MD, FRCPC, James A Russell, MD, Jan Storek, MD, PhD

Blood (2013) 122 (21): 2116.

https://doi.org/10.1182/blood.V122.21.2116.2116

Published: 2013

Journal Articles

Phase I Study of the PARP1-2 Inhibitor Veliparib in Combination with Bortezomib in Patients with Relapsed or Refractory Multiple Myeloma

Paola Neri, MD, PhD, Peter Duggan, MD, FRCPC, Kathy Gratton, Li Ren, PhD, Jordan Johnson, Jiri Slaby, MD, Douglas A. Stewart, MD, FRCP, Jonathan J Keats, PhD, Nizar J. Bahlis, MD

Blood (2012) 120 (21): 1862.

https://doi.org/10.1182/blood.V120.21.1862.1862

Published: 2012

Journal Articles

Prolonged Survival in Secondary CNS Lymphoma Following High Dose Thiotepa/Busulfan-Based Chemotherapy (HDTB) and Autologous Stem Cell Transplantation (ASCT): Single Institution Results From Calgary, Canada

Lesley E. Street, MD, FRCPC, Nizar J. Bahlis, MD, Karen Valentine, MD, PhD, Deirdre A. Jenkins, MD, FRCPC, Carolyn J Owen, MD, FRCPC, Mona Shafey, MD, FRCPC, Peter Duggan, MD, FRCPC, Douglas A. Stewart, MD, FRCPC

Blood (2012) 120 (21): 2003.

https://doi.org/10.1182/blood.V120.21.2003.2003

Published: 2012

Journal Articles

High Cereblon Protein Expression Correlates with Improved Response and Survival in Myeloma Patients Treated with Lenalidomide

Alexander Klimowicz, PhD, Paola Neri, MD, PhD, Andrew Belch, MD, Michelle Dean, Li Ren, PhD, Kathy Gratton, Jiri Slaby, MD, Jordan Johnson, Peter Duggan, MD, FRCPC, Douglas A. Stewart, MD, FRCPC, Nizar J. Bahlis, MD

Blood (2012) 120 (21): 931.

https://doi.org/10.1182/blood.V120.21.931.931

Published: 2012

Journal Articles

Lenalidomide Suppresses 5′-Cap-Independent C-MYC Translation in Multiple Myeloma Cells

Jiri Slaby, MD, Jordan Johnson, Paola Neri, MD, PhD, K Gratton, Li Ren, PhD, Douglas A. Stewart, MD, FRCP, Peter Duggan, MD, FRCPC, Nizar J. Bahlis, MD

Blood (2012) 120 (21): 3943.

https://doi.org/10.1182/blood.V120.21.3943.3943

Published: 2012

Journal Articles

A miRNA Risk Score for the Prediction of Response to Lenalidomide in Multiple Myeloma (MM) Patients

Paola Neri, MD, PhD, Andrew R Belch, MD, Jordan Johnson, Kathy J Gratton, Li Ren, PhD, Peter Duggan, MD, FRCPC, Adnan Mansoor, MD, FCPS, FRCP(C), FCAP, Douglas A. Stewart, MD, FRCP, Nizar Bahlis, MD

Blood (2011) 118 (21): 987.

https://doi.org/10.1182/blood.V118.21.987.987

Published: 2011

Journal Articles

Mir-34a Sensitizes Multiple Myeloma (MM) Cells to the Proteasome Inhibitor Bortezomib

Erin Stebner, Paola Neri, MD, PhD, Jordan Johnson, Kathy J Gratton, Li Ren, PhD, Peter Duggan, MD, FRCPC, Douglas A. Stewart, MD, FRCP, Nizar Bahlis, MD

Blood (2011) 118 (21): 138.

https://doi.org/10.1182/blood.V118.21.138.138

Published: 2011

NARROW

Cite-Seq Profiling of T Cells in Multiple Myeloma Patients Undergoing BCMA Targeting CAR-T or Bites Immunotherapy

Is Tandem ASCT Needed in MM Patients with High Risk Cytogenetics in the Era of Maintenance Therapy? Results from the Canadian Myeloma Research Group (CMRG) Database

Bortezomib-Maintenance for Patients with AL Amyloidosis: A Single Center Experience

Early Relapse in Transplant-Eligible MM Patients Undergoing Auto-SCT Followed By Maintenance Therapy

Post-Autologous Stem Cell Transplantation Therapy for Multiple Myeloma Patients: Impact on Clinical Outcomes

Single Cell Resolution Profiling Defines the Innate and Adaptive Immune Repertoires Modulated By Daratumumab and IMiDs Treatment in Multiple Myeloma (MM)

Phase I/II Study of Infusional Gemcitabine and High-Dose Melphalan Conditioning Prior to Autologous Stem Cell Transplantation for Patients with Relapsed/Refractory Lymphoma: Interim Safety Analysis

Minimal Residual Disease (MRD) Assessed By Flow Cytometry in Patients with AL Amyloidosis Treated with Cyclophosphamide, Bortezomib and Dexamethasone (CyBorD)

The Evolving Impact on Survival Outcomes in Multiple Myeloma with Greater Access to Novel Treatment Regimens: Experience in a Real-World Cohort

Impact of ABO Incompatibility on Engraftment in Allogeneic Hematopoietic Stem Cell Transplantation

Development of Second Primary Malignancies in Multiple Myeloma Patients Treated with Lenalidomide: An Alberta Perspective

BK Virus Hemorrhagic Cystitis Is Associated with Graft Versus Host Disease and Increased Health Care Resource Utilization in Patients Undergoing Allogeneic Stem Cell Transplantation

Outcomes and Correlative Studies Of a Phase I Trial With The Oral PARP1-2 Inhibitor Veliparib In Combination With Bortezomib In Patients With Relapsed Or Refractory Multiple Myeloma

Fludarabine Metabolite Level On Day Zero Does Not Affect Outcomes Of Hematopoietic Cell Transplantation In Patients With Normal Renal Function

Phase I Study of the PARP1-2 Inhibitor Veliparib in Combination with Bortezomib in Patients with Relapsed or Refractory Multiple Myeloma

Prolonged Survival in Secondary CNS Lymphoma Following High Dose Thiotepa/Busulfan-Based Chemotherapy (HDTB) and Autologous Stem Cell Transplantation (ASCT): Single Institution Results From Calgary, Canada

High Cereblon Protein Expression Correlates with Improved Response and Survival in Myeloma Patients Treated with Lenalidomide

Lenalidomide Suppresses 5′-Cap-Independent C-MYC Translation in Multiple Myeloma Cells

A miRNA Risk Score for the Prediction of Response to Lenalidomide in Multiple Myeloma (MM) Patients

Mir-34a Sensitizes Multiple Myeloma (MM) Cells to the Proteasome Inhibitor Bortezomib

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only